Radiodermatitis– - Pipeline Insight, 2025

DelveInsight’s, “Radiodermatitis - Pipeline Insight, 2025,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Radiodermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Radiodermatitis Understanding

Radiodermatitis: Overview

Radiation dermatitis is a side effect of external beam ionizing radiation. It is also known as radiodermatitis, x-ray dermatitis, radiation skin damage or a radiation burn. Most commonly, radiation-induced dermatitis is caused by radiotherapy for underlying malignancies. It may also occur due to the exposure to radiation during interventional procedures such as coronary angiography, embolization procedures, and indwelling catheter placements. Irradiation of the skin leads to a complex pattern of direct tissue injury involving damage to cells of the epidermis and endothelial cells within the walls of blood vessels, and inflammatory cell recruitment. Many small studies have investigated the use of topical therapies, as either preventative agents or for management of skin reactions as they occur.

""Radiodermatitis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Radiodermatitis pipeline landscape is provided which includes the disease overview and Radiodermatitis treatment guidelines. The assessment part of the report embraces, in depth Radiodermatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Radiodermatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Radiodermatitis R&D. The therapies under development are focused on novel approaches to treat/improve Radiodermatitis.

Radiodermatitis Emerging Drugs Chapters

This segment of the Radiodermatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Radiodermatitis Emerging Drugs

• TEMPOL: Matrix Biomed

TEMPOL (4-hydroxy-2,2,6,6-TetraMethylPiperidine-1-OxyL) represents a promising compound for the treatment and prevention of numerous diseases and conditions. TEMPOL is a stable free radical that readily reacts with toxic oxygen species including superoxide (O2.-), hydroxyl radical (.OH), and secondary radicals produced by the oxidation of biological macromolecules, including lipid radicals. TEMPOL reaches every cell in the body and repairs damaged cellular environments thereby increasing mitochondria output and improving overall cellular function. Currently, in phase II of clinical trials for the treatment of Radiodermatitis.

• LUT 014: Lutris Pharma

Lutris Phama develops the topical B-Raf inhibitor LUT014, a proprietary small molecule that allows administration of epidermal growth factor receptor (EGFR) inhibitors to patients without the interruptions caused by typical cutaneous side effects. Lutris Pharma plans a phase I/II trial for Radiodermatitis (In adults, In the elderly) in breast cancer patients in Israel.

Further product details are provided in the report……..

Radiodermatitis: Therapeutic Assessment

This segment of the report provides insights about the different Radiodermatitis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Radiodermatitis

There are approx. 3+ key companies which are developing the therapies for Radiodermatitis. The companies which have their Radiodermatitis drug candidates in the mid to advanced stage, i.e. Phase II include, Matrix Biomed and others.

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase II/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Radiodermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Parenteral
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Polymer
• Peptide
• Gene Therapy
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Radiodermatitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Radiodermatitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Radiodermatitis drugs.

Radiodermatitis Report Insights

• Radiodermatitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Radiodermatitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Radiodermatitis drugs?
• How many Radiodermatitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Radiodermatitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Radiodermatitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Radiodermatitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Matrix Biomed
• Lutris Pharma
• FirstString Research
• Joben Bio-Medical

Key Products

• TEMPOL
• LUT 014
• ACT 1
• JBM-TC4